Trial Profile
Phase II Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma 54179060LYM2003 (Nick Name: IVORY Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2020
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms IVORY Study
- 19 Oct 2020 Status changed from active, no longer recruiting to completed.
- 01 Jun 2020 Primary endpoint (complete response rate) has not been met.
- 01 Jun 2020 Results published in the Annals of Hematology.